EGFR Mutation
AstraZeneca’s Tagrisso dominates lung cancer market with projected $7B sales by 2025
Anika Sharma
The lung cancer drug market has been notably dominated by antibodies and immunotherapies, but a recent report from GlobalData suggests ...
Lazertinib Beats Gefitinib in Treating EGFR-Mutated NSCLC
SG Tylor
In a Phase III study known as LASER301 (NCT04248829) and published in the Journal of Clinical Oncology, lazertinib (formerly YH25448), ...
